[{"id":"4344444c-75d7-40a8-8d13-8d1190b703c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00620321","created_at":"2021-01-18T02:18:20.529Z","updated_at":"2024-07-02T16:36:55.902Z","phase":"Phase 2","brief_title":"A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT00620321","lead_sponsor":"Eli Lilly and Company","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • gataparsen (LY2181308)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 01/01/2010","primary_completion_date":" 01/01/2010","study_txt":" Completion: 01/01/2010","study_completion_date":" 01/01/2010","last_update_posted":"2019-09-09"}]